100 related articles for article (PubMed ID: 21742829)
21. Harnessing the power of prevention: human papillomavirus vaccines.
Mayeaux EJ
Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s15-21. PubMed ID: 16520680
[TBL] [Abstract][Full Text] [Related]
22. Cost-utility analysis of vaccination against HPV in Israel.
Ginsberg GM; Fisher M; Ben-Shahar I; Bornstein J
Vaccine; 2007 Sep; 25(37-38):6677-91. PubMed ID: 17706844
[TBL] [Abstract][Full Text] [Related]
23. Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme.
Oteng B; Marra F; Lynd LD; Ogilvie G; Patrick D; Marra CA
Sex Transm Infect; 2011 Feb; 87(1):52-7. PubMed ID: 20956352
[TBL] [Abstract][Full Text] [Related]
24. [Vaccination against HPV in adults].
Gil Á
Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():22-5. PubMed ID: 20084345
[No Abstract] [Full Text] [Related]
25. HPV vaccine: beyond the hype.
Consum Rep; 2007 Oct; 72(10):47. PubMed ID: 17912799
[No Abstract] [Full Text] [Related]
26. Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis.
Accetta G; Biggeri A; Carreras G; Lippi G; Carozzi FM; Confortini M; Zappa M; Paci E
J Med Screen; 2010; 17(4):181-9. PubMed ID: 21258128
[TBL] [Abstract][Full Text] [Related]
27. Mothers' intention for their daughters and themselves to receive the human papillomavirus vaccine: a national study of nurses.
Kahn JA; Ding L; Huang B; Zimet GD; Rosenthal SL; Frazier AL
Pediatrics; 2009 Jun; 123(6):1439-45. PubMed ID: 19482752
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of human papilloma virus vaccination in Iceland.
Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T
Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
[TBL] [Abstract][Full Text] [Related]
29. HPV vaccine and its recommendations, 2007.
Zimmerman RK
J Fam Pract; 2007 Feb; 56(2 Suppl Vaccines):S1-5, C1. PubMed ID: 17270106
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
Rogoza RM; Westra TA; Ferko N; Tamminga JJ; Drummond MF; Daemen T; Wilschut JC; Postma MJ
Vaccine; 2009 Jul; 27(35):4776-83. PubMed ID: 19539578
[TBL] [Abstract][Full Text] [Related]
31. Prospects for cervical cancer prevention by human papillomavirus vaccination.
Schiller JT; Lowy DR
Cancer Res; 2006 Nov; 66(21):10229-32. PubMed ID: 17079437
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM; van Ballegooijen M; Habbema JD
J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
[TBL] [Abstract][Full Text] [Related]
33. Post-licensure monitoring of HPV vaccine in the United States.
Markowitz LE; Hariri S; Unger ER; Saraiya M; Datta SD; Dunne EF
Vaccine; 2010 Jul; 28(30):4731-7. PubMed ID: 20188681
[TBL] [Abstract][Full Text] [Related]
34. Impact of vaccinating boys and men against HPV in the United States.
Elbasha EH; Dasbach EJ
Vaccine; 2010 Oct; 28(42):6858-67. PubMed ID: 20713101
[TBL] [Abstract][Full Text] [Related]
35. [In defence of women against HPV-infection].
Blázovics A
Orv Hetil; 2007 Apr; 148(17):813. PubMed ID: 17452313
[No Abstract] [Full Text] [Related]
36. [Condyloma typing important for follow up of HPV vaccination. A condyloma reporting project].
Sturegård E; Johnsson A; Gustafsson E; Dillner J
Lakartidningen; 2008 Dec 10-16; 105(50):3648-50. PubMed ID: 19177930
[No Abstract] [Full Text] [Related]
37. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
Westra TA; Daemen T; Postma MJ; Wilschut JC
Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
[TBL] [Abstract][Full Text] [Related]
38. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
Schiffman M
Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
[TBL] [Abstract][Full Text] [Related]
39. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia.
Gertig DM; Brotherton JM; Saville M
Sex Health; 2011 Jun; 8(2):171-8. PubMed ID: 21592430
[TBL] [Abstract][Full Text] [Related]
40. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.
Bonanni P; Cohet C; Kjaer SK; Latham NB; Lambert PH; Reisinger K; Haupt RM
Vaccine; 2010 Jul; 28(30):4719-30. PubMed ID: 20451636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
